Industry: Healthcare
Published Date: August-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 170
Report ID: PMRREP34715
The global bioresorbable vascular scaffold market is estimated to value at US$592.8 Mn by the end of 2031 from US$314.4 Mn recorded in 2023. The market is expected to secure a CAGR of 8.3% in the forthcoming years from 2024 to 2031.
Key Highlights of the Market
|
Market Attributes |
Key Insights |
|
Bioresorbable Vascular Scaffold Market Size (2024E) |
US$339.0 Mn |
|
Projected Market Value (2031F) |
US$592.8 Mn |
|
Forecast Growth Rate (CAGR 2024 to 2031) |
8.3% |
|
Historical Growth Rate (CAGR 2018 to 2023) |
7.3% |
A bioresorbable vascular scaffold (BVS) represents an innovative approach in interventional cardiology, designed to treat coronary artery disease while gradually being absorbed by the body over time.
Unlike traditional metal stents, BVS provides temporary support to the artery and then dissolves, allowing the vessel to regain natural function. This technology reduces long-term complications associated with permanent implants, such as restenosis and thrombosis.
The advancements in biodegradable materials and manufacturing techniques, promises improved patient outcomes and reduced need for long-term dual antiplatelet therapy.
Scaffolds are being designed with features to better withstand vascular dynamics and adapt to the complexities of individual patient anatomies.
The next-generation designs aim to reduce mechanical stress on arterial walls while providing robust support during the critical healing period post-implantation.
Innovations in this field represent a paradigm shift towards personalized medicine in interventional cardiology, where tailored scaffold properties and enhanced biocompatibility are poised to improve clinical outcomes and patient satisfaction.
As regulatory approvals and clinical validations progress, these advancements are expected to redefine standards in vascular care, offering safer and more effective solutions for coronary artery disease treatment.
The bioresorbable vascular scaffold (BVS) market has witnessed significant growth since its inception, driven by advancements in material science, improved clinical outcomes, and growing preference for minimally invasive procedures in cardiology.
Initially introduced to address limitations of traditional metallic stents, BVS technology has evolved rapidly, supported by favorable clinical trials demonstrating efficacy and safety.
Looking ahead, the market is poised for continued expansion with ongoing research focusing on enhancing scaffold design, biocompatibility, and resorption kinetics.
Innovations in polymer technology and manufacturing processes aim to optimize scaffold performance, reducing risks of complications like late stent thrombosis and improving long-term patient outcomes. Regulatory approvals and increasing adoption in key markets worldwide further contribute to market growth.
Challenges remain, including ensuring consistent performance across patient demographics and refining deployment techniques. However, strategic collaborations between medical device companies, research institutions, and healthcare providers are expected to drive innovation and address these challenges.
As demand for minimally invasive cardiovascular interventions grows, BVS holds promise as a pivotal technology in the future landscape of interventional cardiology.
Incorporation of Digital Health Solutions
Digital health integration is emerging as a pivotal driving factor in the evolution of bioresorbable vascular scaffold (BVS) technologies.
By incorporating digital health solutions, such as wearable devices and remote monitoring systems, healthcare providers track patient recovery in real-time post-procedure. This integration enables early detection of complications, personalized adjustment of treatment plans, and proactive management of patient care.
Moreover, digital tools facilitate data-driven insights into patient outcomes, contributing to continuous improvement in scaffold design and procedural techniques.
Ultimately, digital health integration enhances the overall efficacy and safety of BVS implementations, paving the way for more precise and patient-centered cardiovascular interventions.
Growing CVD Cases and Increasing Demand for MIS Procedures
The rising incidence of cardiovascular disease (CVD) globally has fuelled an increasing demand for minimally invasive procedures (MIS), including the use of bioresorbable vascular scaffolds.
Patients with CVD often seek treatments offering effective outcomes with fewer risks and faster recovery times. MIS techniques, characterized by smaller incisions and reduced trauma to the body, align closely with these patient preferences. They allow for quicker rehabilitation and return to normal daily activities compared to traditional surgical approaches.
Bioresorbable vascular scaffold represents a promising advancement in interventional cardiology, offering temporary support to coronary arteries during healing while eventually dissolving naturally.
This feature addresses concerns about the long-term presence of permanent implants, such as metallic stents, which may pose ongoing risks or necessitate prolonged medical therapy.
The combination of increasing awareness of MIS benefits, coupled with the rising prevalence of CVD, underscores BVS as a pivotal technology in meeting the evolving needs of cardiovascular care globally.
Long-term Safety and Efficacy, and Biocompatibility Concerns
Long-term safety, efficacy, biocompatibility concerns, and mechanical strength limitations are critical challenges faced by players manufacturing bioresorbable vascular scaffolds.
Ensuring that these scaffolds degrade as intended without compromising structural integrity over time is crucial for patient safety and treatment efficacy.
Biocompatibility concerns arise from the body's response to the scaffold material, affecting tissue integration and healing processes. Meanwhile, achieving sufficient mechanical strength to support vascular structures while degrading at a controlled rate remains a technological hurdle.
Addressing these interconnected challenges requires rigorous research and development efforts focused on improving material science, enhancing scaffold design, and conducting comprehensive long-term clinical trials to validate safety and efficacy profiles. These efforts are essential to overcoming barriers and advancing the adoption of bioresorbable vascular scaffolds in clinical practice.
Complex Manufacturing Process
Complex manufacturing processes pose a significant challenge for bioresorbable vascular scaffold manufacturers, particularly concerning scaling up production and ensuring consistent quality. These scaffolds require precise engineering of biocompatible materials with specific degradation rates and mechanical properties.
Achieving uniformity in scaffold characteristics across large-scale production runs is crucial to ensure reliability and safety in clinical applications.
However, the intricacies involved in biomaterial processing, scaffold design, and assembly can lead to variability in product performance. Addressing these challenges requires advanced manufacturing technologies and stringent quality control measures to meet regulatory standards and satisfy clinical demands for reliable and effective bioresorbable vascular scaffolds.
Increasing Regulatory Support and R&D Investments
The bioresorbable vascular scaffold market is poised for growth due to a favorable regulatory environment and significant investments in research and development.
Regulatory bodies worldwide are increasingly supportive of innovative medical devices, expediting approval processes and facilitating market entry. This environment encourages manufacturers to develop advanced technologies with confidence, knowing that regulatory hurdles are manageable.
Simultaneously, substantial R&D investments by key industry players are pivotal. These investments drive continuous innovation in biomaterials, manufacturing techniques, and product design.
Improved biocompatibility, mechanical properties, and overall safety of bioresorbable scaffolds are outcomes of these efforts. Such advancements not only address current clinical challenges but also open new possibilities for personalized medicine and improved patient outcomes.
Furthermore, R&D initiatives ensure that bioresorbable vascular scaffolds meet stringent regulatory requirements and clinical efficacy standards. This synergy between regulatory support and R&D investments underscores the market's potential for expansion and underscores its attractiveness to stakeholders seeking sustainable growth in healthcare innovation.
Technological Advancements and Innovation
Advancements in material science present a significant opportunity in the bioresorbable vascular scaffold manufacturers by enabling the development of novel biocompatible materials that enhance scaffold performance and biodegradation rates.
Biocompatibility is crucial in reducing adverse reactions and promoting tissue integration, thereby improving patient outcomes.
Innovations in material science including biocompatible polymers and coatings, allow for the creation of scaffolds with tailored mechanical properties, such as flexibility and radial strength, which are essential for supporting blood vessels effectively during the healing process.
Moreover, advancements in biodegradation technology can lead to scaffolds that degrade predictably and safely over time, minimizing long-term complications and allowing for natural vessel healing without permanent implants.
Furthermore, advancements in imaging techniques and biomaterials research are likely to support personalized treatment strategies, optimizing patient outcomes.
With increasing research investments and collaborations between academia and industry, the bioresorbable vascular scaffold market is poised for significant growth and evolution.
|
Category |
Projected CAGR through 2031 |
|
Application – Coronary Artery |
7.55% |
|
End User- Hospitals |
8.43% |
Application of BVS in Coronary Artery Segment to Account for a Significant Share
The application in coronary artery segment is set to dominate the global market in 2023 and is likely to maintain its dominance during in the forthcoming years recording a CAGR of 7.55%.
Coronary artery disease remains a major health concern globally, driving the demand for effective and less invasive treatment options. BVS offer advantages over traditional metal stents by providing temporary support to the artery and gradually absorbing into the body, potentially reducing long-term complications.
Additionally, advancements in BVS technology have enhanced their efficacy and safety profile, making them increasingly favored among healthcare providers and patients alike. As a result, the coronary artery segment is poised to dominate the BVS market share, addressing substantial clinical needs in cardiovascular care.
Hospitals Represent a Sizeable Share of Global Market
Hospitals account for a significant share in the global industry. Hospitals are primary centers for cardiovascular procedures where BVS are predominantly used for treating coronary artery disease. The availability of skilled healthcare professionals and advanced medical infrastructure in hospitals ensures the safe and effective deployment of BVS devices.
Furthermore, hospitals often have dedicated cardiac catheterization labs equipped with specialized imaging technologies necessary for precise placement of scaffolds. Additionally, hospitals play a crucial role in patient care continuity, post-procedural monitoring, and follow-up, further solidifying their significant contribution to the BVS market worldwide.
|
Region |
CAGR through 2034 |
|
North America |
7.70% |
|
East Asia |
9.21% |
North America to Account for the Significant Market Share
North America is a significant shareholder in the global market and is expected to grow at a CAGR of 7.70% during the forecast period. The region boasts a well-established healthcare infrastructure coupled with high healthcare expenditure, enabling swift adoption of advanced medical technologies like bioresorbable scaffolds.
A large patient pool suffering from cardiovascular diseases, including coronary artery disease, drives the demand for effective treatment options such as bioresorbable vascular scaffolds.
Thirdly, robust research and development activities in the healthcare sector and strong support from regulatory bodies for innovative medical devices contribute to market growth.
Moreover, favorable reimbursement policies and high awareness among healthcare professionals and patients about the benefits of bioresorbable scaffolds further bolster market penetration in North America. These factors collectively position North America as a prominent market for bioresorbable vascular scaffolds.
East Asia All Set to Exhibit a Notable CAGR
East Asia Market is projected to secure a CAGR of 9.21% in the forecast period from 2024 to 2031. The region’s increasing healthcare expenditure and advancements in medical technology drive demand for innovative cardiovascular treatments.
Furthermore, growing awareness among healthcare professionals and patients about the benefits of bioresorbable scaffolds over traditional stents is accelerating adoption.
Additionally, favorable government initiatives supporting healthcare infrastructure development and rising cases of cardiovascular diseases contribute to market growth.
With expanding access to advanced healthcare facilities and a rising aging population prone to cardiac ailments, East Asia presents a fertile ground for the bioresorbable vascular scaffold market's expansion.
Growing investments in R& D to develop, launch and expand product portfolio is a key strategy observed in the last couple of years. The leading industry players are expanding their manufacturing capabilities and simultaneously their presence in the global market, thereby, boosting the global market for bioresorbable vascular scaffolds.
Recent Industry Developments
In Apr 2024, Abbott’s Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System) received U.S.FDA approval for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The system help keep the arteries open to deliver drug (Everolimus) and support vessel healing prior to completely dissolving.
In Feb 2024, Biotronik launched Freesolve™ Resorbable Magnesium Scaffold (RMS) as well as announced its CE approval. Freesolve™ is a 3rd generation RMS to achieve magnesium resorption within 12 months and provide optimized vessel support.
In Jun 2023, Zeus developed and launched Absorv™ XSE oriented tubing, a next-generation tubing for bioresorbable vascular scaffolds. Absorv XSE offers an alternative to metallic products implanted permanently in the human body.
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2018 to 2023 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled in the Report |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product
By Application
By End User
By Region
To know more about delivery timeline for this report Contact Sales
The increasing demand for bioresorbable vascular scaffold is driven by its applications in treating coronary artery disease and growing demand for minimally invasive procedures.
Some of the key players operating in the market are Meril Life Sciences Pvt. Ltd., Zeus Company LLC, Biotronik, Abbott, MicroPort Scientific Corporation, Kyoto Medical, and Elixir Medical (MedImpact Healthcare Systems, Inc.)
The application in coronary artery treatment segment recorded the significant market share in 2023.
Targeting emerging economies with growing healthcare infrastructure, rising incidence of cardiovascular diseases and expansion of product lines to include variations in scaffold design, sizes, and materials to cater to diverse patient needs and anatomies are estimated to present opportunities for the market players.
North America is set to account for the most significant share of the market.
